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Therapy for microsporidia, which cause diarrhea and a wasting syndrome in persons with AIDS, has had limited success. Fumagillin, a naturally secreted water-insoluble antibiotic, has in vitro activity against microsporidia and has been used successfully in the treatment of superficial keratitis in patients with AIDS, but systemic therapy has been limited by toxicity of the currently available fumagillin salt. TNP-470, a semisynthetic analogue of fumagillin, was studied in vitro and in the athymic nude mouse model of microsporidiosis. RK13 cells were infected with microsporidia of the family Encephalitozoonidae and treated at day 3 with TNP-470. This agent was highly effective, with an ID 50 (50% inhibitory dose compared with control) of 0.001 mg/mL. TNP-470 also demonstrated in vivo activity against Encephalitozoon cuniculi, with prolonged survival and the prevention of the development of ascites in infected athymic mice. These data suggest that the fumagillin derivative TNP-470 is a promising agent for the treatment of microsporidiosis.
Microsporidia, obligate, intracellular, spore-forming paracytozoon bieneusi causes most microsporidia-related disease in the United States; however, many other microsporidia gensites, cause diarrhea and a wasting syndrome in persons with era have been described as the etiologic agent in human dis-AIDS. Although microsporidia have been described in immueases. nocompetent patients, most cases occur in AIDS patients with Three Encephalitozoonidae members have been associated suppressed CD4 cell counts [1] . In this setting, microsporidia with disease in humans: Encephalitozoon cuniculi, Encephalicause a wasting syndrome associated with diarrhea and malabtozoon hellem, and Encephalitozoon intestinalis (previously sorption [2] . Of the microsporidia that infect humans, Enteroknown as Septata intestinalis) [1] . It appears that these microsporidia can disseminate widely in their hosts, and involvement of most organs by these organisms has now been docu-was chosen as the reference standard for Encephalitozoonidae bestrated persistence of organisms in treated responders [4] . drug, the parasite count returned to pretreatment levels [6] .
In experiment 1, TNP-470 was injected ip starting 3 days after
The mechanism of action of fumagillin is not known. Possible nium) [7] ; however, systemic treatment in mammals has been
For experiments 2 and 3, the intravenous (iv) formulation that limited due to the toxicity of fumagillin bicyclohexammonium. was used consisted of TNP-470 (10 mg/mL), G2 b-cyclodextrin (72.6 mg/mL), and NaOH (33.3 mg/mL) when reconstituted in TNP-470, a potent semisynthetic analogue of fumagillin, has sterile water. The formulation was diluted in distilled water to potent antiangiogenic activity and is relatively nontoxic in provide the appropriate end concentrations of 10, 50, and 100 mg/ mammals [8] . Given the activity of fumagillin against mikg in a volume of 0.3-0.5 mL. The experiments were designed to crosporidia, we examined the antimicrosporidial effect of this test suppression of microsporidia, not to cure infection. Uninfected drug in vitro and in a mouse model of disseminated microsporicontrol mice were used to monitor mortality from drug, and indiosis.
fected control mice were used to monitor the rate of ascites development and mortality due to microsporidia.
Statistical analysis. Data were analyzed by Student's t test or
Materials and Methods
nonparametric analysis (Mann-Whitney rank sum and Wilcoxon's RK13 (rabbit kidney) cells (ATTC CCL37) were maintained in signed rank tests), using SigmaStat (version 2.0; Jandel Scientific, culture in MEM supplemented with 10% heat-inactivated fetal calf San Rafael, CA). serum, 1% penicillin, and 1% streptomycin as previously described [9] . These cells were infected with Enc. cuniculi, Enc. hellem, or Enc. intestinalis spores in microwell plates. TNP-470 (TAP
Results
Pharmaceutical, Deerfield, IL) was dissolved in DMSO (Sigma, St. Louis) at a concentration of 1 mg/mL. plates infected with Enc. cuniculi, 10.6% of the RK13 cells mg/mL. Enc. intestinalis was screened at 0.1 and 0.01 mg/mL.
In vitro experiments. By day 7 after infection (see table
were infected, while at an antimicrosporidial concentration of and Vittaforma corneae demonstrated antimicrosporidial activ- 100 mg/kg three times a week, clinical toxicity (ruffled fur and death) was observed within 2 weeks. Fumagillin, the parent compound of TNP-470, has clinical hellem, Enc. cuniculi, or Enc. intestinalis, was 0.0625 mg/mL.
effectiveness, but it is limited by its toxicity when administered We did not examine the ability of the Encephalitozoonidae to iv. Fumagillin bicyclohexammonium, an agricultural product regrow after a 9-day exposure to this drug followed by cultivaused for the treatment of nosematosis in honey bees, has been tion in the absence of drug. However, at §0.5 mg/mL TNPsuccessfully used in humans to treat Enc. hellem infection of 470, no organisms were evident at the light microscopic level, the superficial cornea and conjunctiva (keratoconjunctivitis or and no organisms could be found by electron microscopy.
punctate epithelial keratopathy) that is seen mainly in patients In vivo experiments. TNP-470 also demonstrated signifiwith AIDS [1, 2] . The clinical response to topical fumagillin cant in vivo activity against Encephalitozoonidae (table 2) . In for this condition is well described [7] . TNP-470 is a potent experiment 1 (using TNP-470 in ethanol), 100 mg/kg per day angiogenesis inhibitor that is very effective in inhibiting endowas toxic to mice, as evidenced by ruffled fur and premature thelial cell proliferation in both in vitro and in vivo models, death. A dosage of 50 mg three times a week was tolerated, although the action of this drug on endothelial cells has not and survival was increased in infected mice. The mean length been elucidated [12] . Currently, phase II human clinical trials of survival (LOS) ({SE) after infection was 37 { 0.5 days for of this drug as an angiogenesis inhibitor are underway. Given infected untreated mice and 44 { 1 days for mice given TNPthe activity of TNP-470 against Enc. hellem, its minimal in 470 (50 mg/kg) ip three times a week (P õ .05).
vitro toxicity to mammalian cells, and its antiangiogenic propIn experiment 2, no toxicity was seen with TNP-470 at 50 erties (minimizing angiogenesis as a consequence of infection), mg/kg per day using the iv (i.e., clinical) formulation of TNPthis drug may be very useful as a topical agent for the treatment 470 (10 mg/mL TNP-470, 72.6 mg/mL G2 b-cyclodextrin, of microsporidian keratoconjunctivitis. and 33.3 mg/mL NaOH when reconstituted in sterile water).
Recently, fumagillin has been used to successfully treat miUntreated mice had an LOS of 38 { 0.5 days after infection. crosporidia of the family Enterocytozoonidae: Ent. bieneusi in Mice treated with TNP-470 at 10 mg/kg per day had an LOS of 44 { 1 days, and at 50 mg/kg per day, no mortality was seen by day 55, at which time the experiment was terminated Table 2 . Activity of TNP-470 in athymic mice infected with Entero-(P õ .05 for increased survival with treatment). In the present study, we demonstrated that TNP-470 is a † P õ .05. ‡ P õ .05 drug treatment vs. no treatment.
highly active antimicrosporidial agent both in vitro and in vivo.
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